From the FDA Drug Label
INDICATIONS AND USAGE CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable (1)
The FDA drug label does not answer the question.
From the Research
Upadacitinib is currently considered the most effective JAK inhibitor for atopic dermatitis, with superior efficacy in clinical trials compared to other JAK inhibitors like abrocitinib and baricitinib, as demonstrated in a network meta-analysis 1. At the approved dose of 15-30mg once daily, upadacitinib has shown significant improvement in itch within days and skin clearance within weeks. The key benefits of upadacitinib include:
- Superior efficacy in achieving symptomatic relief and improving disease severity
- Favorable safety profile, with monitoring required for potential side effects such as infections, blood clots, and laboratory abnormalities
- Oral administration, making it a convenient option for patients Other JAK inhibitors approved for atopic dermatitis include abrocitinib (100-200mg daily) and baricitinib (2-4mg daily), which are also effective but generally show somewhat lower response rates in comparative analyses 1, 2. When prescribing any JAK inhibitor, it's essential to monitor for potential side effects and individualize treatment based on patient characteristics, comorbidities, and insurance coverage, as efficacy differences may be outweighed by other factors in specific patient scenarios 3, 4. A recent study also showed that switching from baricitinib 4 mg to upadacitinib 30 mg can effectively improve rash and pruritus in patients with moderate-to-severe atopic dermatitis 5.